GlassScriptPhysician profile
Shunian He
NPI 1740207471
$8,148.30
in general payments reported to CMS, 2019-2025
39 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $946 · 2021: $1,124 · 2022: $954 · 2023: $1,144 · 2024: $1,382 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,897.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,208.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,130.28 | 2021-2025 | |
| Novo Nordisk INC | $835.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $573.25 | 2019-2025 | |
| Lilly USA, LLC | $553.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $406.87 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $346.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $276.87 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $255.04 | 2022-2025 | |
| Glaxosmithkline, LLC. | $194.95 | 2019-2022 | |
| Lundbeck LLC | $175.17 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $170.94 | 2023-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $170.79 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $167.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $161.31 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shunian He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.